Why Investors Should Keep an Eye on the Oklahoma Opioid Trial Against Johnson & JohnsonThe Motley Fool • 06/07/19
Pharma Stock Roundup: ASCO Update, FDA Nod for LLY's Emgality for Cluster HeadacheZacks Investment Research • 06/07/19
Oklahoma prosecutors blast J&J in first day of landmark opioid trial. Say drugmaker ran ‘deceitful, multibillion-dollar brainwashing campaign’CNBC • 05/28/19